Century Therapeutics Q4 2023 Earnings Report $0.44 -0.02 (-4.34%) As of 04/4/2025 04:00 PM Eastern Earnings HistoryForecast Century Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.56Beat/MissBeat by +$0.07One Year Ago EPSN/ACentury Therapeutics Revenue ResultsActual Revenue$0.27 millionExpected Revenue$1.69 millionBeat/MissMissed by -$1.42 millionYoY Revenue GrowthN/ACentury Therapeutics Announcement DetailsQuarterQ4 2023Date3/14/2024TimeN/AConference Call ResourcesPress ReleaseIPSC Earnings HistoryPowered by Remove Ads Century Therapeutics Earnings HeadlinesHC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00April 6 at 3:11 AM | americanbankingnews.comCentury Therapeutics' (IPSC) Buy Rating Reiterated at GuggenheimMarch 29, 2025 | americanbankingnews.comFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…April 6, 2025 | Colonial Metals (Ad)Brokers Set Expectations for IPSC FY2025 EarningsMarch 29, 2025 | americanbankingnews.comCentury Therapeutics price target lowered to $5 from $12 at GuggenheimMarch 21, 2025 | markets.businessinsider.comCentury Therapeutics Announces Pipeline Re-Prioritization to Focus on Transformational Programs and Extends Cash Runway into Q4 2026March 21, 2025 | nasdaq.comSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
